Actively Recruiting
Study of PLG0206 to Prevent Recurrent Infection in Adults Undergoing DAIR Surgery for Prosthetic Joint Infection After Knee Replacement
Led by Peptilogics · Updated on 2026-10-26
240
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational drug PLG0206 to see if it can help reduce the recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR Debridement, Antibiotics, and Implant Retention surgical procedure to treat a Prosthetic Joint Infection PJI. This Phase 23 randomized, placebo-controlled study also aims to assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will undergo the DAIR procedure according to their hospitals standard of care. After debridement, they will receive a single dose of either PLG0206 or a placebo as an intra-articular irrigation solution. Following the procedure, all participants will receive standard post-operative care including possible IV or oral antibiotics and will be discharged according to local practices. Participants will be monitored for approximately one year after the procedure for safety and signs of infection recurrence. Study visits will be in-clinic on Days 14, 90, and 365, with additional telephone or virtual visits on Days 30, 180, and 270. Researchers will measure treatment failure rates, safety outcomes, clinical effectiveness, microbiological results, biomarker changes, and functional improvements throughout the study period.
CONDITIONS
Brief Title
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Research Team
P
Peptilogics RETAIN Study Lead
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here